DoJ joins off-label suit against J&J
Executive Summary
The Department of Justice has intervened in two whistleblower suits claiming Scios and parent Johnson & Johnson marketed Natrecor (nesiritide) for off-label use. The drug was approved in 2001 for treatment of acute heart failure and DoJ says Scios shortly thereafter began an aggressive campaign marketing it for scheduled, serial outpatient infusions for patients with less severe heart failure. J&J acquired Scios in 2003. Former Scios sales managers filed separate False Claim Act suits against Scios and J&J in the Northern District of California
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.